Veracyte VCYT Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $264.79M-27.3% | $364.23M+14.8% | $317.21M+43.4% | $221.15M+17.8% | $187.77M-22.0% | ||
| $50.11M+12.2% | $44.66M-6.6% | $47.83M-5.9% | $50.81M-5.5% | $53.78M+15.6% | ||
| $522.18M+6.9% | $488.38M+8.7% | $449.22M+8.3% | $414.68M+8.2% | $383.15M+2.9% | ||
| $22.65M+2.1% | $22.19M+17.4% | $18.9M+1.9% | $18.55M-17.7% | $22.53M-1.8% | ||
| $767.15M0.0% | $767.15M0.0% | $767.15M-0.8% | $773.26M+2.5% | $754.27M+1.1% | ||
| $79.66M-4.0% | $82.95M-3.9% | $86.28M-3.7% | $89.61M+4.7% | $85.59M-16.3% | ||
| —— | —— | —— | —— | —— | ||
| $1.44B+2.2% | $1.41B+2.8% | $1.37B+1.8% | $1.34B+2.2% | $1.32B+1.2% | ||
| $6.91M+50.4% | $4.59M-16.6% | $5.51M-51.9% | $11.45M-27.1% | $15.71M+81.9% | ||
| $749K-35.4% | $1.16M+178% | $417K-71.2% | $1.45M-15.3% | $1.71M+2.3% | ||
| $56.12M-6.4% | $59.94M-16.9% | $72.15M-5.6% | $76.43M+1.7% | $75.13M-4.5% | ||
| $91.99M-4.6% | $96.44M-12.4% | $110.12M-10.5% | $123.05M+2.1% | $120.48M-2.9% | ||
| 125M0.0% | 125M0.0% | 125M0.0% | 125M0.0% | 125M+160,156% | ||
| -$348.92M+7.6% | -$377.63M+9.8% | -$418.78M+4.4% | -$437.92M-0.2% | -$436.94M+1.6% | ||
| $1.34B+2.7% | $1.31B+4.1% | $1.26B+3.0% | $1.22B+2.2% | $1.19B+1.6% | ||
| $1.44B+2.2% | $1.41B+2.8% | $1.37B+1.8% | $1.34B+2.2% | $1.32B+1.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Veracyte cover its short-term obligations?
- Its current ratio is 9.31 — current assets exceed current liabilities.
- Where does Veracyte's balance sheet data come from?
- Every line is extracted from Veracyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.